Compare Nu Holdings Ltd (NU) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nu Holdings Ltd vs Repligen Corporation Common Stock — how do they compare? Nu Holdings Ltd trades at $14.64 (market cap $75.26B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Nu Holdings Ltd is far larger — about 6.8× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Nu Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nu Holdings Ltd for 53 Days and Repligen Corporation Common Stock for 0 Days on average.
| NU | RGEN | |
|---|---|---|
Market Cap | $75.26B | $11.14B |
Volume | 60,119,584 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $18.76 | $194.57 |
52-Week Low | $11.60 | $102.87 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $97.88B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NU stock trades at $14.93, down 6.75% over 24 hours amid recent volatility. The technical outlook is bullish based on moving averages, though the 6-day RSI at 88.3 suggests overbought conditions. Fundamentally, the company shows strong growth with revenue rising from $3.0B in 2022 to $10.63B in 2025 and net income margin improving to 26.99%. Recent news includes denial of Monzo acquisition talks, causing price swings.
The outlook remains positive given robust fundamentals and analyst consensus, but risks include high valuation multiples, credit concentration, and acquisition speculation volatility. Upside to the $16.53 price target offers potential, though investor caution is warranted near technical resistance.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
